Norgen Biotek launches Hantavirus and Ebola detection kits

Norgen Biotek on Oct. 15, 2026 launched new molecular diagnostic kits for Hantavirus and Ebola virus detection, expanding its biodefence portfolio. The company says the kits are designed for field-ready surveillance with a sample-to-result workflow for health and defense users.

Why it matters: - The new kits give public health and defense teams a faster way to screen for two high-consequence viral threats. - Norgen Biotek is moving deeper into biodefence, where speed, sensitivity and simpler workflows can affect outbreak response and biosecurity planning.

What happened: - Norgen Biotek Corp. launched Hantavirus and Ebola Virus Detection Kits on Oct. 15, 2026. - The launch expands Norgen Biotek’s biodefence offering into high-consequence pathogen surveillance. - Dr. Yousef Haj-Ahmad, Norgen Biotek’s president and CEO, said the company is expanding its biodefence footprint to address global health and security challenges.

The details: - The kits are designed as field-ready molecular diagnostics for rapid detection of Hantavirus and Ebola threats. - Norgen Biotek says the workflow combines safe specimen collection, high-yield RNA extraction and RT-qPCR detection in a single pipeline. - The company says the integrated workflow removes bottlenecks in sample processing and threat surveillance. - Norgen Biotek says the kits are intended for defense agencies, public health labs and research institutions. - The company says the kits use proprietary Silicon Carbide (SiC) extraction chemistry paired with sensitive RT-qPCR detection. - Norgen Biotek says the system is built to deliver accurate identification across complex sample types. - The company also positions the kits as part of a broader portfolio of collection, preservation and isolation technologies.

Between the lines: - The launch signals a push from sample prep into end-to-end biodefence diagnostics, which could make Norgen Biotek more relevant in emergency response workflows. - The emphasis on a complete sample-to-result system suggests the company is competing on speed and operational simplicity, not just assay performance.

What's next: - Norgen Biotek said it expects the new kits to support rapid response to emerging infectious disease threats. - The company directs readers to more information for details about its products and company background.

The bottom line: - Norgen Biotek is broadening from molecular tools into biodefence testing with kits aimed at faster, field-ready detection of Hantavirus and Ebola.